drugset
Drugs / scAAV2/8-LP1-hFIXco
last change Mar 2026 re-read 3 minutes ago

scAAV2/8-LP1-hFIXco

Developed for
hemophilia B
Investigated by
Children's Hospital of Philadelphia · Hemophilia of Georgia, Inc. · National Heart, Lung, and Blood Institute (NHLBI) · St. Jude Children's Research Hospital · University College, London

Trials 1

today NCT00979238 · Ph 1
201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00979238 Feb 2010 → Mar 2026 hemophilia B St. Jude Children's Research Hospital Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as scAAV2/8-LP1-hFIXco ClinicalTrials.gov intervention name — accepted as the source's own label NCT00979238 ↗
Route Intravenous “A single intravenous infusion of the scAAV2/8-LP1-hFIXco vector” PMID 40499172 ↗ Jun 2025